Excipients Portfolio Now Includes Polymers for Sustained Release InjectablesIssue: August 24, 2016
| Category: Formulations
Our excipients portfolio has expanded to now include 38 polymers for sustained release of small molecule and selected peptide injectables, allowing customers to optimize and precisely control release kinetics of final drug products. Expansorb® PLA and PLGA polymers are manufactured following ICHQ7 Chapter 19 standards (for use in clinical trials) and are expected to be sold under our industry-leading Emprove® program, once rigorous evaluations and certifications are complete. The ability to better control and sustain the release of drugs allows for delivery via reduced numbers of injections with the same therapeutic efficacy, improving patient comfort and compliance. Providing drug developers with a means of protecting molecules with short in vivo half-lives and maintaining the desired therapeutic effect incentivized us to introduce Expansorb® polymers to our broad portfolio of excipients. Click here for more information. EXPANSORB® is a registered trademark of Groupe PCAS, Longjumeau, France. In This Same Issue |
Recent Articles
Article Search
Article Archives
Events
Webinars
|